Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167245 · ClinicalTrials.gov registry record · Phase 2
Topiramate for Alcohol and Cocaine Dependence
A Phase 2 study of Alcoholism and Cocaine Dependence, sponsored by Kyle Kampman.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT00167245: Completed Phase 2 study of Alcoholism and Cocaine Dependence, sponsored by Kyle Kampman.
NCT00167245 is a Phase 2 study of Alcoholism and Cocaine Dependence that has completed, run by Kyle Kampman. The registered enrollment target is 170 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00167245, a Phase 2 study of Alcoholism and Cocaine Dependence, has completed, sponsored by Kyle Kampman.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
Primary Outcome
Samples were analyzed for benzoylecgonine by fluorescent polarization assay. Samples containing equal to or greater than 300 ng/ml of benzoylecgonine were considered to be positive for cocaine.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Topiramate
Study Locations (1)
Pennsylvania
- University of Pennsylvania, Treatment Research Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00167245 record still lists
NCT00167245 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (54% lower).
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00167245 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00167245 about?
NCT00167245 is a clinical study titled "Topiramate for Alcohol and Cocaine Dependence". The primary purpose of this study is to test the effectiveness of topiramate for the treatment of combined alcohol and cocaine dependence. Topiramate is approved for the treatment of seizures. It has not been proven to be effective for the treatment of alcohol or cocaine dependence.
What is the current status of trial NCT00167245?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2004-09. Estimated completion is 2010-06.
What conditions does trial NCT00167245 study?
This clinical trial studies the following conditions: Alcoholism, Cocaine Dependence.
What interventions are being tested in trial NCT00167245?
The interventions under investigation include: placebo (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT00167245?
This trial is sponsored by Kyle Kampman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00167245 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00167245's enrollment target sits among peer trials
170 23rd of 65 higher than 43 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia